OrthoPediatrics: The Super Cycle Sells the Story, the Legacy Portfolio Pays the Bills

OrthoPediatrics walked into its October 27 print with the stock up 31% over ninety trading days — one clean, uninterrupted ramp — and walked out having raised revenue guidance. The headline is a record quarter. The more interesting story is the divergence between what is compounding today and what management keeps telling investors will compound tomorrow.

The quarter where cash finally showed up

Revenue was $72.7 million, up 19% from $61.2 million, with trauma and deformity at $52.6 million (+19%), scoliosis at $19.2 million (+18%) and international at $14.8 million (+18%) despite deliberately suppressed set sales into Brazil. Adjusted EBITDA hit a record $6.9 million, roughly a 10% margin, and year-to-date that figure is $16 million against $10 million a year ago — a 60% improvement on 16% revenue growth. That is genuine operating leverage, not a mix footnote.

The number that matters most is the cash line. “Free cash flow generated in the third quarter of 26 was $1.6 million compared to $3.4 million used in the third quarter of 25.” — Fred L. Hite, Chief Operating and Financial Officer · 2026-10-27 Set deployment fell to $2.5 million from $4.1 million a year earlier, and the full-year capital commitment is running near $10 million versus far higher levels in prior years. The company has been promising a free cash flow breakeven year for several quarters; it is now one quarter away, needing roughly $6 million in Q4 after generating $10 million in last year's Q4. Free cash flow (less stock comp) was negative $7 million in the June quarter and only just turned positive in September. That trajectory, more than any product launch, is what has re-rated the equity.

The super cycle keeps moving to the right

Here is the tension. The Super Cycle has been the organising keyword of this story for four consecutive quarters — it is not a new theme, it is a drumbeat. What changed this quarter is the calendar. In April the CEO said plainly: “We expect first surgeries for both Ellie and Veraxis by the end of the year.” — David R. Bailey, President and Chief Executive Officer · 2026-04-30 Seven months later:

It certainly does not look like we will be doing surgeries by the end of this year, but looks like into early 27... It will have some impact on 2027, but it will probably be in a limited release fashion. This is more a 2028, 2029 story.

The same rightward drift applies across the board. PNP Retrograde, cleared by the FDA in late September with first cases in October, is not expected to reach full market release until mid-2027. The 3P Small and Mini systems remain in limited launch: “first half of next year type of story when we move into full market release.” — David R. Bailey, President and Chief Executive Officer · 2026-10-27 Even VerteGlide, the one genuinely scaling new product with roughly 125 surgeons trained and 40-plus hospitals using it, is described as "a story for us in 2027." Note the keyword record: the concept of the beta launch was among the biggest decliners in the latest quarter's momentum history after quarters of prominence — the language of imminent launches has quietly given way to the language of training, service and clinical feedback.

None of this is fatal. Management is explicit that it is rationing sets to protect cash, and the capital-efficiency argument is real:

These sets are more efficient. They are far more capital efficient with higher ASPs, higher margin, and they return cash faster.

But it does mean the revenue in front of us is not coming from the super cycle. It is coming from the shelf.

The old catalogue is doing the lifting

Look at the company's own keyword ranking for this quarter: legacy product jumped to second place, right behind clinic expansion. That is not the ranking of a launch story. That is the ranking of a share-gain story, and the CEO said so without hedging: “The number 1 driver of growth for us is gaining market share within the legacy products.” — David R. Bailey, President and Chief Executive Officer · 2026-10-27 Cannulated screws, flexible nails, PNP Femur — the commoditised end of the bag — are being pulled through by a widening portfolio and by competitors leaving the field. That exit dynamic has been visible for over a year: “We've seen that from J&J. We've seen that from Smith & Nephew in the last 6 months.” — David Bailey, President and Chief Executive Officer · 2025-10-28

The contracting consequence is the most under-discussed item on the call. Bundling a portfolio nobody else can match lets OrthoPediatrics convert pricing agreements into sole-source or narrow dual-vendor arrangements capturing “50, 60, 70, maybe even 80% market share” — David R. Bailey, President and Chief Executive Officer · 2026-10-27 — and critically, that pull-through requires almost no incremental set capital. That is why revenue can grow 19% while set spend halves.

Two things management has stopped leaning on. First, 7D: a single unit placed, described as "not a major growth driver," with the CFO stating future placements will not be counted in guidance at all. After years of 7D unit sales topping the keyword rankings, it has become a rounding error conceptually. Second, the bracing franchise is where the real non-surgical engine sits — more than 60 clinics, 34 OPSB systems versus 31 at the start of the year, DF2 in roughly half of the ~300 US children's hospitals, TRAXIO sold out of its initial units, and the quirky Knee TractorFIX launching into the external-fixation installed base. This segment grows above 20% with no consignment inventory — a structurally better business than the implant one, even if it dilutes gross margin.

What you are actually paying for

The equity has been de-rated almost beyond recognition: price to revenue sits near 1.9x against a 14.0x peak in 2021, an 86% compression. At a $622 million market cap, the market is no longer paying for the super cycle; it is paying for the cash inflection and throwing in the pipeline for free. The stock peaked at $26.50 in mid-August and sits about 10% below that, so this print lands into strength, not into a drawdown.

Which raises the stakes on the balance sheet. Effective net cash has flipped from +$119 million at the end of 2022 to roughly -$60 million today. Liabilities to assets have climbed from 14% in 2024 to nearly 33%, and receivables still run at 86% of revenue — the Brazil collection problem that has appeared in three consecutive calls. The company has $45 million of cash and $20 million of undrawn term loan, which is adequate, not ample.

The bull case is straightforward and now measurable: a mid-teens grower with 74% gross margins, expanding EBITDA, positive free cash flow, and a pipeline of genuinely differentiated pediatric-only devices that no large OEM wants to build. The bear case is that the super cycle has been one year away for four consecutive years — “At this stage, we are in the batter's box” — David R. Bailey, President and Chief Executive Officer · 2026-04-30 was said in February, and in October we are still being told the biggest revenue impact is 2027 and beyond. In between, the growth is real but comes from the oldest products in the bag. That is a perfectly good business. It is just not the one the launch narrative promises — and the multiple now reflects the difference.